Company Primapharm Life Science Srl with Fiscal Code 29569137
recorded a turnover of 2024 of
81.268,
with a net profit of
1.022.405
and having an average number of employees of
1.
The company operates in the field of Comerţ cu ridicata al produselor farmaceutice și medicale having the NACE code 4646.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Primapharm Life Science Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
229.471
20.145
144.469
311.448
305.887
303.950
300.496
225.262
273.047
81.268
Total Income - EUR
229.476
20.312
145.979
311.449
2.623.923
337.052
970.525
1.565.475
844.036
1.269.224
Total Expenses - EUR
184.326
209.129
351.011
225.533
219.765
218.344
215.885
392.634
408.972
246.818
Gross Profit/Loss - EUR
45.151
-188.817
-205.033
85.916
2.404.157
118.708
754.640
1.172.840
435.065
1.022.405
Net Profit/Loss - EUR
37.927
-188.817
-234.351
81.420
2.376.392
115.337
751.695
1.169.011
432.508
1.022.405
Employees
1
1
1
1
1
1
1
1
1
1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales decreased by -70.1%, from 273.047 euro in the year 2023, to 81.268 euro in 2024.
The Net Profit increased by 592.314 euro, from 432.508 euro in 2023, to 1.022.405 in the last year.
Check the financial reports for the company - Primapharm Life Science Srl
Financial Rating - PRIMAPHARM LIFE SCIENCE SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Primapharm Life Science Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Primapharm Life Science Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Primapharm Life Science Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Primapharm Life Science Srl - CUI 29569137
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Fixed Assets
1.826.978
1.866.974
4.721.822
4.738.956
4.595.504
4.457.274
4.310.044
4.116.462
4.864.877
4.771.890
Current Assets
415.428
529.722
365.413
645.735
1.994.295
1.092.984
1.245.847
1.422.541
1.519.533
1.534.955
Inventories
46.173
103.502
3.698
3.630
3.559
3.492
3.415
3.425
0
0
Receivables
355.988
426.134
361.619
642.055
1.861.731
1.089.451
1.241.604
1.419.075
1.692.494
1.711.713
Cash
13.267
86
97
50
129.005
41
829
41
-172.961
-176.758
Shareholders Funds
393.505
199.033
2.846.335
2.875.520
4.829.234
4.139.646
4.078.410
4.110.856
4.658.336
4.473.820
Social Capital
45
45
574
563
552
542
530
531
530
527
Debts
1.848.902
2.198.309
2.241.588
2.509.170
1.760.566
1.410.612
1.477.482
1.428.148
1.726.546
1.833.025
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9743
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
Main CAEN
"4646 - 4646"
CAEN Financial Year
4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
1.534.955 euro in 2024 which includes Inventories of
0 euro, Receivables of
1.711.713 euro and cash availability of
-176.758 euro.
The company's Equity was valued at
4.473.820 euro, while total Liabilities amounted to
1.833.025 euro.
Equity decreased by -158.481 euro, from 4.658.336 euro in 2023, to 4.473.820 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Primapharm Life Science Srl